Virus Therapy
Gene Therapy for Hemophilia A
Recruiting1 awardPhase 1 & 2
Little Rock, Arkansas
This trial is testing a new gene therapy to treat hemophilia A by delivering a healthy copy of the gene that's missing or defective in people with the disease. Researchers want to find the optimal dose of the therapy so that the body can produce enough clotting factor on its own.
Virus Therapy
Gene Therapy for Hemophilia A
Recruiting1 awardPhase 1 & 2
Lexington, Kentucky
This trial tests a gene therapy that uses a harmless virus to deliver a healthy gene to adults with severe haemophilia A. The goal is to help their bodies produce a missing blood-clotting protein, potentially curing their condition. Gene therapy for hemophilia has been explored for many years, with several programs in advanced stages.
Monoclonal Antibodies
Concizumab for Hemophilia
Recruiting2 awardsPhase 3
Orange, California
This trial tests concizumab, a new medicine, in people with hemophilia A or B who have inhibitors. It aims to see if concizumab can prevent bleeding by helping the blood clot more effectively. Concizumab has shown good results in earlier studies for hemophilia A and B.
Monoclonal Antibodies
Concizumab for Hemophilia
Recruiting2 awardsPhase 3
Detroit, Michigan
This trial tests concizumab, a new daily injectable medicine, in people with haemophilia A or B without inhibitors. The goal is to see if it can safely prevent bleeding episodes. Participants will either start the new medicine immediately or after a period of time, depending on their current treatment plan. Concizumab has shown significant reduction in bleeding rates in previous trials.
Popular Filters
Trials for Hemophilia Patients
Gene Therapy
Gene Therapy for Hemophilia A
Recruiting1 awardPhase 1 & 2
Little Rock, Arkansas
This trial is testing a new gene therapy for hemophilia A patients. It uses a harmless virus to help liver cells produce a missing protein needed for blood clotting. This could reduce the need for frequent injections. The therapy aims to provide a long-term solution by enabling the body to produce the necessary protein on its own.
Recombinant Factor VIII
Efanesoctocog Alfa for Hemophilia A
Recruiting2 awardsPhase 3
Las Vegas, Nevada
This trial is looking at the long-term safety of a drug called BIVV001 in people with hemophilia A. It will also look at how well the drug works to prevent and treat bleeding episodes, and the drug's effect on joint health and quality of life.
Gene Therapy
Gene Therapy for Hemophilia A
Recruiting2 awardsPhase 3
Mountain View, California
This trial tests a single treatment for adult males with severe hemophilia A. The treatment aims to help their bodies produce a necessary protein, reducing the need for regular preventive treatments. Research has been ongoing for a long time to enable the body to produce this protein and reduce bleeding episodes.
Gene Therapy
Gene Therapy for Hemophilia A
Recruiting2 awardsPhase 3
Saint Louis, Missouri
This trial tests a new gene therapy combined with anti-inflammatory medication for patients with severe hemophilia A. The treatment aims to help their bodies produce a necessary clotting protein and reduce inflammation.
Monoclonal Antibodies
Emicizumab for Hemophilia A
Recruiting2 awardsPhase 3
Los Angeles, California
This trial tests emicizumab, a medication that helps blood clot, in people with mild or moderate hemophilia A. It works by mimicking a missing protein to improve blood clotting. Emicizumab has been approved for treatment of hemophilia A patients.
Trials for Hemophilia B Patients
Monoclonal Antibodies
Marstacimab for Hemophilia
Recruiting2 awardsPhase 3
Hamilton, Ontario/canada
This trial tests the safety & effectiveness of a new medicine to prevent bleeding episodes in pediatric hemophilia patients. Participants will get weekly subcutaneous shots & visit the study site 10 times over 14 months. Some visits may be done at home.
Monoclonal Antibodies
Marstacimab for Hemophilia
Recruiting2 awardsPhase 3
New Hyde Park, New York
This trial is an extension of a previous study to assess the long-term safety and efficacy of a prophylactic treatment for hemophilia A and B. Approximately 145 participants will receive injections of the marstacimab drug once weekly for the duration of the study.
Gene Therapy
Factor IX Gene Therapy for Hemophilia B
Recruiting2 awardsPhase 3
San Francisco, California
This trial tests a new gene therapy treatment for adult men with severe hemophilia B. The treatment aims to help their bodies produce a crucial blood-clotting protein. Participants will receive one dose and be monitored over several years to see if it reduces their bleeding episodes. Gene therapy for hemophilia B has shown promising results in recent studies, suggesting potential long-term therapeutic production of the coagulant protein.
Phase 3 Trials
Recombinant Factor VIII
Efanesoctocog Alfa for Hemophilia A
Recruiting2 awardsPhase 3
Las Vegas, Nevada
This trial is looking at the long-term safety of a drug called BIVV001 in people with hemophilia A. It will also look at how well the drug works to prevent and treat bleeding episodes, and the drug's effect on joint health and quality of life.
Gene Therapy
Gene Therapy for Hemophilia A
Recruiting2 awardsPhase 3
Mountain View, California
This trial tests a single treatment for adult males with severe hemophilia A. The treatment aims to help their bodies produce a necessary protein, reducing the need for regular preventive treatments. Research has been ongoing for a long time to enable the body to produce this protein and reduce bleeding episodes.
Gene Therapy
Gene Therapy for Hemophilia A
Recruiting2 awardsPhase 3
Saint Louis, Missouri
This trial tests a new gene therapy combined with anti-inflammatory medication for patients with severe hemophilia A. The treatment aims to help their bodies produce a necessary clotting protein and reduce inflammation.
Monoclonal Antibodies
Emicizumab for Hemophilia A
Recruiting2 awardsPhase 3
Los Angeles, California
This trial tests emicizumab, a medication that helps blood clot, in people with mild or moderate hemophilia A. It works by mimicking a missing protein to improve blood clotting. Emicizumab has been approved for treatment of hemophilia A patients.
Monoclonal Antibodies
Marstacimab for Hemophilia
Recruiting2 awardsPhase 3
Hamilton, Ontario/canada
This trial tests the safety & effectiveness of a new medicine to prevent bleeding episodes in pediatric hemophilia patients. Participants will get weekly subcutaneous shots & visit the study site 10 times over 14 months. Some visits may be done at home.
Trials With No Placebo
Gene Therapy
Gene Therapy for Hemophilia A
Recruiting1 awardPhase 1 & 2
Little Rock, Arkansas
This trial is testing a new gene therapy for hemophilia A patients. It uses a harmless virus to help liver cells produce a missing protein needed for blood clotting. This could reduce the need for frequent injections. The therapy aims to provide a long-term solution by enabling the body to produce the necessary protein on its own.
Recombinant Factor VIII
Efanesoctocog Alfa for Hemophilia A
Recruiting2 awardsPhase 3
Las Vegas, Nevada
This trial is looking at the long-term safety of a drug called BIVV001 in people with hemophilia A. It will also look at how well the drug works to prevent and treat bleeding episodes, and the drug's effect on joint health and quality of life.
Gene Therapy
Gene Therapy for Hemophilia A
Recruiting2 awardsPhase 3
Mountain View, California
This trial tests a single treatment for adult males with severe hemophilia A. The treatment aims to help their bodies produce a necessary protein, reducing the need for regular preventive treatments. Research has been ongoing for a long time to enable the body to produce this protein and reduce bleeding episodes.
Gene Therapy
Gene Therapy for Hemophilia A
Recruiting2 awardsPhase 3
Saint Louis, Missouri
This trial tests a new gene therapy combined with anti-inflammatory medication for patients with severe hemophilia A. The treatment aims to help their bodies produce a necessary clotting protein and reduce inflammation.
Monoclonal Antibodies
Emicizumab for Hemophilia A
Recruiting2 awardsPhase 3
Los Angeles, California
This trial tests emicizumab, a medication that helps blood clot, in people with mild or moderate hemophilia A. It works by mimicking a missing protein to improve blood clotting. Emicizumab has been approved for treatment of hemophilia A patients.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.